Search

Showing 21 - 30 of 430 results.

Regent™ Features

REGENT™ REGENT™ GIVES YOU IMPLANTABILITY OPTIONS TWO DISTINCT CUFF TYPES PROVIDE YOU WITH DIFFERENT OPTIONS *Measured one-year post-surgery. © Abbott 2025. All rights reserved. 9-EH-5-15060-01 0
Patients who benefit

EXCELLENT FUNCTION AND DURABILITY THROUGHOUT A PATIENT’S LIFETIME Although the prevalence of mitral valve disease is 2 to 3 times higher than aortic valve disease, aortic valve surgeries (excluding t
Voice of the experts

STABLE DELIVERY. REMARKABLE PERFORMANCE. FUTURE READY. STABLE DELIVERY REMARKABLE PERFORMANCE FUTURE READY WATCH TAVI SUMMIT: TAVI SUMMIT 2024 TAVI SUMMIT 2023 © Abbott 202
Overview

Two Types of Mitral Regurgitation 1-YEAR MORTALITY UP TO 57%* Mitral regurgitation, if left untreated, initiates a ca
Diagnosis

MR is a progressive disease, and patients may remain asymptomatic even when the condition has become severe, as compensatory mechanisms develop.11 In some cases, the following symptoms may be experi
Overview

See Diagnosis AS is a progressive disease. While patients with AS may initially be asymptomatic, further progression is typically associated with symptoms and poor prognosis.13,14 AS is associa
Diagnosis

The three cardinal symptoms of AS are angina, syncope or heart failure (HF).13,16 Other symptoms include dyspnea and decreased exercise tolerance.14 Primary care physicians should consider AS in ad
Options

Treatment options for aortic stenosis: MEDICAL MANAGEMENT Medical treatment options for symptomatic patients with severe AS are limited. Medical treatment may be helpful in ameliorating symptoms in
Overview

Secondary TR arising from RV remodelling can be classified in three progressive stages26 Initial Right Ventricular (RV) dilatation results in Tricuspid Annulus (TA) dilatation Progressive RV and